Effect and safaty of butylphthalide soft capsules on patients with acute cerebral infarction

Luo Hangli

doi:10.3760/cma.j.issn.1673-4777.2014.02.013

Abstract：Objective To observe the clinical efficacy and safety of butylphthalide soft capsules in the treatment of acute cerebral infarction.Methods A total of 91 patients with acute cerebral infarction were divided into two groups:the control group (n =44) and the observation group (n =47).The control group was given aspirin therapy,according to the condition of given in the conventional treatment for reducing intracranial pressure by using mannitol and glycerol fructose dehydration.The observation group was given conventional treatment combined with butylphthalide soft capsules.Results Before treatment and 2,4 weeks of after treatment,the European stroke scale (ESS) and activity of daily living (Barthel) score were applied to evaluate the clinical efficacy and drug safety.Two groups had different ESS scores after treatment[control group:(47 ± 6),(51 ± 10) scores vs (37 ± 7) scores ; the observation group:(50 ± 7),(64 ± 8) scores vs (35 ± 7) scores],differences were statistically significant (P ＜ 0.05).Mter 4 weeks treatment,ESS score of the observation group compared with the control group,the difference was statistically significant (P ＜ 0.05).Barthel index of two groups after treatment of 2,4 weeks compared with before treatment [control group:(40 ± 10),(56 ± 8) scores vs (30 ± 6) scores; observation group:(45 ± 19),(66 ±9) scores vs (31 ± 16) scores],the differences were statistically significant (P ＜0.05).After 4 weeks treatment,the observation group' s Barthel index compared with the control group,the difference was statistically significant (P ＜ 0.05).The total effective rate was 85.1％ (40/47) in the observation group,and 65.9％ (29/44) in the control group,the difference was statistically significant (P ＜ 0.05).Conclusion Butylphthalide soft capsule has a good curative effect and good security in the treatment of acute cerebral infarction.